Drug Trial Radar · NCT04340362
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jun 8, 2020
Primary completion
Nov 11, 2021
Study completion Dec 9, 2021
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Apr 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).
Conditions
- Glomerulosclerosis, Focal Segmental
Interventions
VX-147Drug
Tablets for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in UPCRTime frame: From Baseline up to Week 13
Locations
44 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham - The Kirklin Clinic
Birmingham, Alabama
California Institute of Renal Research
San Diego, California
The George Washington University Medical Faculty Associates - Kidney Disease & Hypertension
Washington D.C., District of Columbia
Howard University Hospital
Washington D.C., District of Columbia
Kidney and Hypertension Specialists of Miami
Miami, Florida
Florida Premier Research Institute
Winter Park, Florida
Morehouse School of Medicine, Grady Memorial Hospital
Atlanta, Georgia
Children's Healthcare of Atlanta
Atlanta, Georgia
Georgia Nehphrology
Lawrenceville, Georgia
Central Georgia Kidney Specialists PC
Macon, Georgia
Renal Associates of Baton Rouge
Baton Rouge, Louisiana
Ochsner Medical Center - New Orleans
New Orleans, Louisiana
Boston Medical Center
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Renal and Transplant Associates of New England, PC
Springfield, Massachusetts
Paragon Health, PC d/b/a Nephrology Center, PC
Kalamazoo, Michigan
Nephrology and Hypertension Associates, LTD
Tupelo, Mississippi
St Louis Kidney Care
St Louis, Missouri
Nevada Kidney Disease and Hypertension Centers
Las Vegas, Nevada
SUNY Downstate
Brooklyn, New York
Urban Family Practice
Buffalo, New York
Icahn School of Medicine at Mount Sinai
New York, New York
UNC Kidney Center Division of Nephrology & Hypertension
Chapel Hill, North Carolina
Tryon Medical Partners
Charlotte, North Carolina
Durham Nephrology Associates, PA
Durham, North Carolina
Duke University School of Medicine - Duke Molecular Physiology Institute
Durham, North Carolina
Temple University Hospital
Philadelphia, Pennsylvania
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
South Carolina Nephrology and Hypertension Center, Inc.
Orangeburg, South Carolina
Vanderbilt University VU
Nashville, Tennessee
Prolato Clinical Research Center
Houston, Texas
Privia Medical Group
Houston, Texas
Hopital Henri Mondor
Créteil, France
Hôpital Bicêtre AP-HP
Le Kremlin-Bicêtre, France
Bichat Hospital
Paris, France
Hopitaux Universitaires Est Parisien - Hopital Tenon
Paris, France
Service de Nephrologie - Hopital Universitaire Necker
Paris, France
Université Paris-Descartes / Hôpital Européen Georges Pompidou
Paris, France
GCM Medical Group, PSC
San Juan, Puerto Rico
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.